You are viewing: Europe Artificial Intelligence in Drug Discovery Market analysis

The Europe Artificial Intelligence in Drug Discovery Market was valued at $534 Million in 2024 and projected to reach to $1965.9 Million by 2029, representing a compound annual growth rate of 29.8%. Europe's artificial intelligence in drug discovery market is positioned for sustained high-growth expansion through 2029, driven by increasing pharmaceutical R&D budgets and regulatory support for innovative technologies.

Europe Artificial Intelligence in Drug Discovery Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Artificial Intelligence in Drug Discovery Market Trends and Insights

  • This robust growth reflects Europe's strong commitment to advancing pharmaceutical innovation through AI-driven technologies, supported by substantial R&D investments and regulatory frameworks that encourage digital health adoption.
  • Europe's position as a global leader in biotechnology and pharmaceutical research is driving widespread implementation of machine learning and AI algorithms across drug discovery pipelines. The European market benefits from a mature healthcare infrastructure, collaborative research ecosystems, and significant funding from both public and private sectors.
  • Europe's pharmaceutical companies and research institutions are increasingly leveraging AI to accelerate drug candidate identification, optimize clinical trial design, and reduce time-to-market for new therapeutics.
  • Between 2024 and 2029, Europe is expected to consolidate its leadership in AI-enabled drug discovery, with growing adoption among mid-sized biotech firms and established pharmaceutical corporations alike..

Key Market Statistics

  • CAGR (2024-2029) 29.8% CAGR
  • Market Size, 2024 ~USD 534 Million
  • Forecast, 2029 ~USD 1965.9 Million
  • Geography Europe

Europe Artificial Intelligence in Drug Discovery Market Overview

Rapid Market Expansion :

Europe's AI in drug discovery market is valued at $534.0 million in 2024 and is projected to reach $1,965.9 million by 2029, demonstrating exceptional growth momentum across the region.

Strong CAGR Performance :

The European market is growing at a compound annual growth rate of 29.8%, nearly matching the global CAGR of 29.9%, indicating Europe's competitive position in AI-driven pharmaceutical innovation.

Leading European Markets :

The UK leads European adoption with $557.4 million in market size, followed by Germany at $533.1 million and France at $336.7 million, reflecting concentrated innovation hubs across Western Europe.

R&D Investment & Regulatory Support :

Europe's commitment to pharmaceutical innovation is bolstered by substantial R&D investments and supportive regulatory frameworks that accelerate AI technology adoption in drug discovery processes.

Europe Artificial Intelligence in Drug Discovery Market Dynamics

  • The region's established biotech ecosystems, particularly in the UK, Germany, and France, are fostering collaboration between AI developers and pharmaceutical companies, accelerating the adoption of machine learning and computational drug design platforms. The European market will benefit from growing investments in precision medicine, digital health infrastructure, and cross-border research initiatives.
  • Regulatory harmonization through the EMA and EU frameworks is expected to streamline AI-enabled drug approval processes, further incentivizing market growth.
  • Strategic partnerships between European tech companies and pharmaceutical giants will continue to drive innovation and market penetration across the continent..

Market Ecosystem

logo-mobile

AI IN DRUG DISCOVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
GPU-accelerated computing, BioNeMo foundation models, generative AI, molecular simulation, and high-performance computing platforms supporting target discovery, protein engineering, molecular design, and virtual screening Faster AI model training | Accelerated molecular discovery | Reduced computational time | Scalable drug discovery workflows | Improved research productivity
Physics-based molecular modeling, computational chemistry, AI-assisted drug design, virtual screening, and lead optimization through an integrated computational drug discovery platform Higher prediction accuracy | Improved lead optimization | Lower experimental costs | Accelerated candidate selection | Increased probability of clinical success
Generative AI-powered target identification, de novo molecule generation, biomarker discovery, and end-to-end drug discovery through the Pharma.AI platform integrating biology, chemistry, and clinical data Shortened discovery timelines | Rapid identification of novel drug candidates | Improved target validation | Enhanced R&D efficiency | Reduced drug development costs
AI-driven phenomics platform combining high-content cellular imaging, machine learning, automated experimentation, and large-scale biological datasets for target discovery and therapeutic development Faster target identification | Improved biological insights | Higher-quality candidate selection | Increased experimental throughput | Enhanced translational research efficiency
AI foundation models, protein structure prediction, cloud-based AI infrastructure, and multimodal data analytics supporting drug target discovery, molecular modeling, and biomedical research Improved biological understanding | Accelerated target discovery | Scalable AI infrastructure | Enhanced predictive modelling | Faster scientific innovation

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Drug Delivery Devices

Top Technologies
  • Disposable Autoinjectors
  • Reusable Autoinjectors
  • Insulin Pumps
  • Pen Injectors
  • Transdermal Patches
Top Companies
  • Becton, Dickinson and Company
  • Novo nordisk a/s
  • Terumo Corporation
  • Medtronic plc
  • Nipro Corporation

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Analytics

      Top Technologies
      • Natural Language Processing (NLP)
      • Machine Learning
      • Supply Chain Management
      • Predictive Analytics
      • Image Sensors
      Top Companies
      • International Business Machines Corporation
      • MICROSOFT CORPORATION
      • Oracle Corporation
      • SAP SE
      • GOOGLE

        Key Takeaways

        • Europe's AI drug discovery market is valued at $534.0 million in 2024 and will grow to $1,965.9 million by 2029 at a 29.8% CAGR.
        • Europe's strong regulatory environment and R&D infrastructure position the region as a global leader in AI-driven pharmaceutical innovation.
        • Europe's pharmaceutical and biotech sectors are increasingly adopting AI to accelerate drug discovery timelines and reduce development costs.
        • Europe's market growth is driven by collaborative research networks, substantial public funding, and private sector investment in AI technologies.

        Artificial Intelligence in Drug Discovery Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment ANTIBODY & OTHER BIOLOGICS DESIGN (Type)
        Forecast Period 2024-2029
        Growth Rate CAGR of 29.9% from 2024 to 2029
        Largest Segment PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User)
        Market Size Base Year (Billions) ~USD 1.86 (2024)
        Revenue Forecast (Billions) ~USD 6.89 (2029)
        Segments Covered Process, Use Case, Type, Therapeutic Area, Player Type, Ai Tool, Deployment, End User, Process 2022-2029

        Europe Artificial Intelligence in Drug Discovery Market Report Segmentation

        9 segment dimensions are covered across the global market.

        By Process

        • Candidate Selection & Validation
        • Hit Identification & Prioritization
        • Hit-To-Lead Identification/Lead Generation
        • Lead Optimization
        • Target Identification & Selection
        • Target Validation

        By Use Case

        • De Novo Drug Design
        • Drug Optimization
        • Drug Repurposing
        • Safety & Toxicity
        • Understanding Diseases

        By Type

        • Antibody & Other Biologics Design
        • Antibody & Other Biologics Optimization
        • Deep Learning
        • Other Machine Learning Technologies
        • Reinforcement Learning
        • Small Molecule Design
        • Small Molecule Optimization
        • Small-Molecule Design
        • Small-Molecule Optimization
        • Supervised Learning
        • Unsupervised Learning
        • Vaccines Design
        • Vaccines Optimization

        By Therapeutic Area

        • Cardiovascular Diseases
        • Immunology
        • Infectious Diseases
        • Mental Health Disorders
        • Metabolic Diseases
        • Neurology
        • Oncology
        • Other Therapeutic Areas

        By Player Type

        • AI Technology Providers
        • Business Process Service Providers
        • End-To-End Solution Providers
        • Niche/Point Solution Providers

        By Ai Tool

        • Computer Vision
        • Context-Aware Processing & Computing
        • Image Analysis
        • Machine Learning
        • Natural Language Processing

        By Deployment

        • Cloud-Based Deployment
        • On-Premises Deployment
        • SaaS-Based Deployment

        By End User

        • Contract Research Organizations
        • Pharmaceutical & Biotechnology Companies
        • Research Centers And Academic & Government Institutes

        By Process 2022-2029

        • Candidate Selection & Validation
        • Hit Identification & Prioritization
        • Hit-To-Lead Identification/Lead Generation
        • Lead Optimization
        • Target Identification & Selection
        • Target Validation

        Target Audience

        • Pharmaceutical Companies : European pharma firms need market intelligence to optimize AI investments, benchmark R&D spending against competitors, and identify acquisition targets or partnership opportunities in drug discovery.
        • AI & Software Vendors : Technology providers require detailed market data to understand European demand for AI-powered drug discovery solutions, customer segments, and regulatory requirements for market entry.
        • Investment & Private Equity Firms : Investors need comprehensive market analysis to evaluate growth potential, identify promising startups and established players, and assess regional market dynamics for portfolio decisions.
        • Biotech & Research Institutions : Academic and research organizations require market insights to align innovation strategies, secure funding, and understand commercialization pathways for AI-driven drug discovery technologies.
        • Healthcare Consultants & Strategists : Consulting firms and strategic advisors need detailed European market data to guide client recommendations on AI adoption, competitive positioning, and long-term pharmaceutical innovation strategies.

        Europe vs. other regions

        HowEurope compares to the other 3 regional blocs covered in this market.

        North America
        ~USD 3118.4 Million · 30.1% wtd CAGR ·
        Asia Pacific
        ~USD 1384.8 Million · 30.7% wtd CAGR ·
        Latin America
        ~USD 300.1 Million · 27.3% wtd CAGR ·
        Middle East & Africa
        ~USD 124.5 Million · 24.3% wtd CAGR ·

        Countries within Europe - compare and drill down

        Country2025 size (native)
        UKUSD 557.4 Million
        GermanyUSD 533.1 Million
        FranceUSD 336.7 Million
        ItalyUSD 121.8 Million
        SpainUSD 96.4 Million
        Rest Of EuropeUSD 320.5 Million

        Country market size visualization

        UK
        USD 557.4 Million
        Germany
        USD 533.1 Million
        France
        USD 336.7 Million
        Italy
        USD 121.8 Million
        Spain
        USD 96.4 Million
        Rest Of Europe
        USD 320.5 Million

        Reasons to Buy this Report

        • Regional Market Segmentation : Gain detailed insights into Europe's AI drug discovery market with country-level breakdowns for UK, Germany, France, Italy, Spain, and Rest of Europe, enabling targeted market entry strategies.
        • Competitive Landscape Analysis : Understand the competitive positioning of European pharmaceutical and AI companies, identifying key players, partnerships, and innovation hubs driving market growth across the region.
        • Regulatory & Policy Insights : Access comprehensive analysis of European regulatory frameworks, EMA guidelines, and government support mechanisms that influence AI adoption in drug discovery and accelerate market expansion.
        • Investment Opportunity Assessment : Identify high-growth segments and emerging opportunities within Europe's $534M market, with forecasts through 2029 to guide capital allocation and partnership decisions.
        • Technology Adoption Trends : Analyze adoption rates of AI technologies, machine learning platforms, and computational drug design tools across European pharmaceutical companies and research institutions.

        Frequently asked questions

        What is the current size of Europe's AI drug discovery market?

        Europe's AI drug discovery market was valued at $534.0 million in 2024 and is projected to reach $1,965.9 million by 2029.

        What is the expected growth rate for Europe's AI drug discovery market?

        Europe's AI drug discovery market is expected to grow at a compound annual growth rate (CAGR) of 29.8% from 2024 to 2029.

        Which European countries are leading in AI drug discovery adoption?

        Europe's leading markets include the United Kingdom, Germany, France, and Switzerland, which have strong pharmaceutical sectors and significant AI research capabilities.

        What factors are driving growth in Europe's AI drug discovery market?

        Europe's market growth is driven by increased R&D investments, supportive regulatory frameworks, collaborative research ecosystems, and the need to reduce drug development timelines and costs.

        How does Europe's AI drug discovery market compare to other regions?

        Europe represents a significant portion of the global AI drug discovery market, with a 29.8% CAGR comparable to the global rate of 29.9%, reflecting strong regional adoption and innovation.

        RESEARCH METHODOLOGY

        The study involved significant activities in estimating the current size of the AI in drug discovery market. Exhaustive secondary research was done to collect information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in drug discovery market.

        Secondary Research

        This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and Companies House documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

        Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

        Primary Research

        In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

        Primary research was conducted to identify segmentation types; industry trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at.

        In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

        Breakdown of the Primary Respondents:

        AI in Drug Discovery Market Size, and Share

        Note: Other designations include sales managers, marketing managers, and product managers.
        Note: Tiers are defined based on a company’s total revenue as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

        To know about the assumptions considered for the study, download the pdf brochure

        Market Size Estimation

        The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (assessment of utilization/adoption/penetration trends by offering, function, application, deployment, tools, end user, and region).

        AI in Drug Discovery Market : Top-Down and Bottom-Up Approach

        AI in Drug Discovery Market Top Down and Bottom Up Approach

        Data Triangulation

        After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the AI in drug discovery market. 

        Market Definition

        The AI in drug discovery market comprises artificial intelligence-based software platforms and computational solutions that accelerate early-stage drug discovery by enabling target identification, lead optimization, candidate selection, and drug repurposing. These solutions leverage technologies such as machine learning, deep learning, and generative AI to improve R&D efficiency, reduce costs, and shorten drug development timelines.

        Key Stakeholders

        • AI in drug discovery software vendors
        • AI in drug discovery service providers
        • Pharmaceutical companies
        • Biotechnology companies
        • AI technology providers
        • Drug discovery software providers
        • Contract Research Organizations (CROs)
        • Academic and research institutes
        • Clinical research organizations
        • Cloud service and high-performance computing (HPC) providers
        • Genomics and multi-omics data providers
        • Healthcare data and bioinformatics companies
        • Government agencies and regulatory authorities
        • Venture capital firms and strategic investors
        • Healthcare and life sciences consulting firms
        • Contract Development and Manufacturing Organizations (CDMOs)
        • Healthcare providers (involved in translational research)
        • Precision medicine and companion diagnostics companies
        • Life sciences distributors and technology integrators

        Report Objectives

        • To describe and forecast the global AI in drug discovery market, by process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region, in terms of value
        • To provide detailed information regarding the factors such as the drivers, restraints, opportunities, and challenges influencing the growth of the market
        • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in drug discovery market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
        • To forecast the size of the AI in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa, in terms of value
        • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
        • To track and analyze competitive developments such as product & service launches, expansions, partnerships, agreements, collaborations, and acquisitions in the AI in drug discovery market
        • To benchmark players within the AI in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

        Available customizations:

        With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

        Geographic Analysis

        • Further breakdown of the Rest of Europe’s AI in drug discovery market into Denmark, Norway, and others

        • Further breakdown of the Rest of Asia Pacific AI in drug discovery market into Vietnam, New Zealand, Australia, South Korea, and others

        Company Information

        • Detailed analysis and profiling of additional market players (up to 5)

         

        Get the Full Artificial Intelligence in Drug Discovery Market Report

        Full forecast, segment splits, and company analysis for all Artificial Intelligence in Drug Discovery Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status